BONFANTI PAOLO

Squillace, N., Taramasso, L., Ricci, E., Menzaghi, B., Gidari, A., Orofino, G., et al. (2026). Switching to DTG/3TC or FTC/TAF/BIC in people living with HIV already on a stable TAF including regimen does not change weight and lipid profile. In Abstracts from the 18th Italian Conference on AIDS and Antiviral Research (pp.151-152) [10.1136/sextrans-icar-2026.153]. Dettaglio

Costacurta, L., Taramasso, L., Ricci, E., Squillace, N., Orofino, G., Pellicanò, G., et al. (2026). Low-level viremia is associated with incident diabetes in obese people with HIV. In Abstracts from the 18th Italian Conference on AIDS and Antiviral Research (pp.149-150) [10.1136/sextrans-icar-2026.151]. Dettaglio

Cologgi, G., Taramasso, L., Ricci, E., Ferrara, S., Orofino, G., Squillace, N., et al. (2026). Weight and lipid changes after switching to long-acting cabotegravir and rilpivirine. In Abstracts from the 18th Italian Conference on AIDS and Antiviral Research (pp.88-89) [10.1136/sextrans-icar-2026.86]. Dettaglio

Calcagno, A., Candela, C., Riva, A., Calza, S., Fioretti, B., Gardini, S., et al. (2026). Bimonthly Administered Long-Acting Cabotegravir and Rilpivirine Are Highly Effective and Well-Tolerated in People With Human Immunodeficiency Virus Above 65 Years. OPEN FORUM INFECTIOUS DISEASES, 13(1) [10.1093/ofid/ofaf817]. Dettaglio

Meissner, E., Ramgopal, M., Ruane, P., Sanchez, W., Crofoot, G., Routy, J., et al. (2026). Safety and efficacy of switching to bictegravir–lenacapavir versus continuing bictegravir–emtricitabine–tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. THE LANCET. HIV [10.1016/S2352-3018(26)00078-0]. Dettaglio